The stock of TG Therapeutics Inc (NASDAQ:TGTX) hit a new 52-week low and has $4.88 target or 12.00% below today’s $5.55 share price. The 8 months bearish chart indicates high risk for the $298.54M company. The 1-year low was reported on Oct, 31 by Barchart.com. If the $4.88 price target is reached, the company will be worth $35.82 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 136,522 shares traded hands. TG Therapeutics Inc (NASDAQ:TGTX) has declined 34.64% since March 29, 2016 and is downtrending. It has underperformed by 38.12% the S&P500.
Analysts await TG Therapeutics Inc (NASDAQ:TGTX) to report earnings on November, 14. They expect $-0.32 earnings per share, down 14.29% or $0.04 from last year’s $-0.28 per share. After $-0.33 actual earnings per share reported by TG Therapeutics Inc for the previous quarter, Wall Street now forecasts -3.03% EPS growth.
TG Therapeutics Inc (NASDAQ:TGTX) Ratings Coverage
Out of 6 analysts covering TG Therapeutics (NASDAQ:TGTX), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. TG Therapeutics has been the topic of 7 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Friday, May 27 by SunTrust. The stock of TG Therapeutics Inc (NASDAQ:TGTX) earned “Buy” rating by Suntrust Robinson on Friday, May 27. FBR Capital initiated the stock with “Outperform” rating in Tuesday, December 1 report. The stock of TG Therapeutics Inc (NASDAQ:TGTX) earned “Buy” rating by H.C. Wainwright on Wednesday, August 12. As per Wednesday, September 9, the company rating was initiated by Raymond James. On Thursday, October 6 the stock rating was reinitiated by Brean Capital with “Buy”. The firm has “Hold” rating given on Wednesday, August 12 by Zacks.
According to Zacks Investment Research, “TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.”
Insitutional Activity: The institutional sentiment increased to 1.54 in 2016 Q2. Its up 0.09, from 1.45 in 2016Q1. The ratio is positive, as 10 funds sold all TG Therapeutics Inc shares owned while 18 reduced positions. 14 funds bought stakes while 29 increased positions. They now own 29.49 million shares or 0.54% more from 29.33 million shares in 2016Q1.
Blackrock Gp has 17,275 shares for 0% of their US portfolio. Tudor Investment Et Al holds 23,516 shares or 0% of its portfolio. The New York-based Fred Alger Management has invested 0% in TG Therapeutics Inc (NASDAQ:TGTX). The New York-based Jpmorgan Chase has invested 0% in TG Therapeutics Inc (NASDAQ:TGTX). Fmr Limited Liability Com owns 4.86 million shares or 0% of their US portfolio. Stoneridge Inv Prtn Ltd Liability Corporation owns 295,482 shares or 0.27% of their US portfolio. Pictet Asset Mngmt Ltd reported 1.22M shares or 0.04% of all its holdings. Teacher Retirement Systems Of Texas accumulated 0% or 5,939 shares. Rhumbline Advisers last reported 0% of its portfolio in the stock. Moreover, New York State Common Retirement Fund has 0% invested in TG Therapeutics Inc (NASDAQ:TGTX) for 223,851 shares. Metropolitan Life Com Ny holds 25,432 shares or 0% of its portfolio. Northern Corporation holds 0% or 460,288 shares in its portfolio. Baldwin Brothers Inc Ma last reported 0.02% of its portfolio in the stock. Geode Cap Mgmt Limited Company has 277,277 shares for 0% of their US portfolio. Reilly Advsr accumulated 0% or 100 shares.
Insider Transactions: Since July 5, 2016, the stock had 0 insider buys, and 1 sale for $302,052 net activity. 50,426 shares were sold by Power Sean A, worth $302,052.
Another recent and important TG Therapeutics Inc (NASDAQ:TGTX) news was published by Fool.com which published an article titled: “Why TG Therapeutics, Inc. Stock Is Dropping Today” on October 13, 2016.
TGTX Company Profile
TG Therapeutics, Inc. (TG), incorporated on May 18, 1993, is a biopharmaceutical firm focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Firm is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Firm is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Firm also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Firm also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.